324 related articles for article (PubMed ID: 37587450)
1. Eosinophils in the tumor microenvironment: implications for cancer immunotherapy.
Ghaffari S; Rezaei N
J Transl Med; 2023 Aug; 21(1):551. PubMed ID: 37587450
[TBL] [Abstract][Full Text] [Related]
2. Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy.
Grisaru-Tal S; Rothenberg ME; Munitz A
Nat Immunol; 2022 Sep; 23(9):1309-1316. PubMed ID: 36002647
[TBL] [Abstract][Full Text] [Related]
3. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
4. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
5. A new dawn for eosinophils in the tumour microenvironment.
Grisaru-Tal S; Itan M; Klion AD; Munitz A
Nat Rev Cancer; 2020 Oct; 20(10):594-607. PubMed ID: 32678342
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma enhances human eosinophil effector functions induced by granulocyte-macrophage colony-stimulating factor or interleukin-5.
Yamaguchi T; Kimura H; Kurabayashi M; Kozawa K; Kato M
Immunol Lett; 2008 Jun; 118(1):88-95. PubMed ID: 18440651
[TBL] [Abstract][Full Text] [Related]
7. An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy.
Li YR; Yu Y; Kramer A; Hon R; Wilson M; Brown J; Yang L
Cells; 2022 May; 11(9):. PubMed ID: 35563889
[TBL] [Abstract][Full Text] [Related]
8. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
9. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
Ghaedrahmati F; Esmaeil N; Abbaspour M
Cancer Commun (Lond); 2023 Feb; 43(2):177-213. PubMed ID: 36585761
[TBL] [Abstract][Full Text] [Related]
10. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance.
Jiang T; Chen X; Ren X; Yang JM; Cheng Y
Drug Resist Updat; 2021 May; 56():100752. PubMed ID: 33765484
[TBL] [Abstract][Full Text] [Related]
12. IL-5-producing CD4
Blomberg OS; Spagnuolo L; Garner H; Voorwerk L; Isaeva OI; van Dyk E; Bakker N; Chalabi M; Klaver C; Duijst M; Kersten K; Brüggemann M; Pastoors D; Hau CS; Vrijland K; Raeven EAM; Kaldenbach D; Kos K; Afonina IS; Kaptein P; Hoes L; Theelen WSME; Baas P; Voest EE; Beyaert R; Thommen DS; Wessels LFA; de Visser KE; Kok M
Cancer Cell; 2023 Jan; 41(1):106-123.e10. PubMed ID: 36525971
[TBL] [Abstract][Full Text] [Related]
13. Target tumor microenvironment by innate T cells.
Li YR; Wilson M; Yang L
Front Immunol; 2022; 13():999549. PubMed ID: 36275727
[TBL] [Abstract][Full Text] [Related]
14. Innate Immunity in Cancer Biology and Therapy.
Zhang Y; Xue W; Xu C; Nan Y; Mei S; Ju D; Wang S; Zhang X
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37510993
[TBL] [Abstract][Full Text] [Related]
15. GM-CSF: A Double-Edged Sword in Cancer Immunotherapy.
Kumar A; Taghi Khani A; Sanchez Ortiz A; Swaminathan S
Front Immunol; 2022; 13():901277. PubMed ID: 35865534
[TBL] [Abstract][Full Text] [Related]
16. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
Ginefra P; Lorusso G; Vannini N
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
[TBL] [Abstract][Full Text] [Related]
17. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps.
Morshed M; Yousefi S; Stöckle C; Simon HU; Simon D
Allergy; 2012 Sep; 67(9):1127-37. PubMed ID: 22764833
[TBL] [Abstract][Full Text] [Related]
18. The GM-CSF-IRF5 signaling axis in eosinophils promotes antitumor immunity through activation of type 1 T cell responses.
Arnold IC; Artola-Boran M; Gurtner A; Bertram K; Bauer M; Frangez Z; Becher B; Kopf M; Yousefi S; Simon HU; Tzankov A; Müller A
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32970801
[TBL] [Abstract][Full Text] [Related]
19. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
20. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
